Neurological Biomarkers Market size was valued at USD 7 billion in 2021 and expected to reach a value of USD 16 billion by 2028, at a CAGR of 12.9% during the forecast period 2022- 2028. The global neurological biomarkers market is anticipated to record fast growth with the current neurological disorder conditions all across the world. A huge percentage of people are affected by neurological disorders and consequently causing major disabilities around the world. Because of the increasing cases of neurological disorders, demand for biomarkers is increased for measuring biological states. These biomarkers are also utilized for indication of biological and pathogenic process in terms of healing intervention. They are also used in combination to know the illness state of the person. Biomarkers are also used for those who are suffering from acute ischemic stroke, subarachnoid hemorrhage, and brain injury and intracerebral hemorrhage. The recovery of the patients is totally depending on their mitigation. In such type of situation, a delay can be there in proper examination of the patients due to the complexities. This situation calls for the use of biomarkers and promotes the biomarkers market. The research examines COVID-19 in light of changes in consumer behaviour and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. The revised report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.